This page is an English translation of the Korean original. If there is any discrepancy, the Korean version prevails.
| A. Classification codes | ICD-10 C45 (C45.0 mesothelioma of pleura, C45.1 mesothelioma of peritoneum, C45.2 mesothelioma of pericardium, C45.7 other sites, C45.9 unspecified) |
| B. Synonyms | Mesothelioma, malignant pleural mesothelioma (MPM), peritoneal mesothelioma, pericardial mesothelioma, asbestos-related pleural cancer, malignant mesothelioma |
| C. Adult onset | Very high — occurs mainly in adults in their 60s–70s; latency of 30–40 years after asbestos exposure |
| Special Copayment Reduction | V193 · 5 years from the cancer patient registration date · 5% copayment |
| 1. History | Selikoff (1960s) first established the asbestos-mesothelioma association epidemiologically; recognition as an occupational injury; total asbestos ban in Korea in 2009 |
| 2. Causes | Asbestos is the only officially recognized cause (crocidolite and amosite are most dangerous); radiation; SV40 virus (controversial); erionite |
| 3. Genetics | BAP1 (most common, 60%); NF2 (40–50%); CDKN2A (p16) deletion (70–80%); LATS1/2; TMB in relation to immunotherapy |
| 4. Epidemiology | Mesothelioma incidence in Korea increasing (through 2038); 30–40-year latency; people exposed in the past continue to develop the disease even after the asbestos ban |
| 5. Pathophysiology | Asbestos fibers → chronic pleural inflammation → ROS overproduction → NF2/BAP1/CDKN2A variants → malignant transformation of mesothelial cells |
| 6. Symptoms | Dyspnea, chest pain, nonproductive cough (pleural); abdominal distension, abdominal pain (peritoneal); weight loss, fatigue |
| 7. Signs | Pleural effusion, pleural thickening (CT); dullness to percussion; asbestos plaques; ascites (peritoneal); reduced respiratory function |
| 8. Screening | No standard screening test; regular chest CT for people exposed to asbestos; serum mesothelin biomarker; regular occupational disease health checkups |
| 9. Diagnosis | Chest CT/MRI; PET-CT staging; thoracoscopic pleural biopsy (standard); immunohistochemistry (calretinin, WT1, CK5/6); BAP1 loss IHC |
| 10. Treatment | Nivolumab+ipilimumab (first-line standard); pemetrexed+cisplatin (chemotherapy); combination with bevacizumab; surgery (selective); SBRT |
| 11. Prognosis | Median survival 12–21 months; some improvement with immunotherapy; 5-year survival 5–10%; peritoneal mesothelioma somewhat more favorable |
| 12. Prevention | Strict compliance with the total asbestos ban; regulation of demolition of asbestos-containing buildings; medical surveillance of people exposed to asbestos; recognition and compensation as occupational injury |
| 13. References | Selikoff 1965, ASCO 2025 guideline, NEJM CheckMate 743, PMC paper on projected mesothelioma incidence in Korea |
Malignant mesothelioma is a rare but lethal malignancy originating from the mesothelial cells that make up serosal membranes such as the pleura, peritoneum, pericardium and tunica vaginalis. The first clinical descriptions of mesothelioma date back to the late 19th century, but it was established as a distinct pathologic entity in the mid-20th century.
The most decisive turning point in the history of mesothelioma was the research of the American occupational physician Irving J. Selikoff in the 1960s. Presenting a cohort study of asbestos workers at the 1964 American Medical Association (AMA) meeting, Selikoff was the first to demonstrate epidemiologically a strong causal relationship between asbestos exposure and malignant pleural mesothelioma. Despite strong opposition from the asbestos industry at the time, this became the scientific basis for strengthening asbestos regulation worldwide over the following decades.
In the 1960s–1980s, mesothelioma incidence surged in countries with active asbestos industries (the UK, Australia, the US, Japan, etc.). Many countries began to regulate or ban asbestos use, and Korea banned all uses of asbestos entirely in 2009. However, because the latency between asbestos exposure and mesothelioma is very long, at 30–40 years, mesothelioma incidence is projected to keep rising for decades even after the asbestos ban.
In the history of treatment, survival improved for the first time when pemetrexed+cisplatin was established as the first-line standard chemotherapy in 2003. Adding bevacizumab subsequently showed benefit in some patients, and the CheckMate 743 trial published in 2020 demonstrated that nivolumab+ipilimumab combination immunotherapy improves overall survival compared with chemotherapy, leading to FDA approval as first-line treatment in 2020.
Among the causes of malignant mesothelioma, asbestos is overwhelmingly the most important and is virtually the only officially recognized major cause.
Asbestos is broadly divided into amphibole asbestos and serpentine asbestos (chrysotile/serpentine asbestos). Crocidolite and amosite (both amphiboles) are the most carcinogenic, and chrysotile, though relatively less so, also increases mesothelioma risk. Asbestos fibers reach the pleura via the lungs, or reach the peritoneum through direct or indirect exposure to asbestos-containing products. Representative occupations with asbestos exposure include shipbuilding, construction (use of insulation and soundproofing materials), manufacturing, mining, and railway and automobile repair.
Erionite is a fibrous mineral that caused clusters of mesothelioma in some villages in Turkey and has a carcinogenic mechanism similar to asbestos. Radiation exposure is also known to increase mesothelioma risk. The hypothesis that SV40 (Simian Virus 40) may be involved in human mesothelioma has been raised, but it remains controversial and a causal relationship has not been clearly established. Those with BAP1 germline variants have markedly increased susceptibility to mesothelioma, and the risk is multiplied through interaction with asbestos exposure.
Malignant mesothelioma has a lower TMB than other cancers, and its main genomic feature is inactivation of tumor suppressor genes rather than specific activating variants.
BAP1 (BRCA1-associated protein-1) is the most frequently altered gene in mesothelioma, with loss confirmed in about 60% of malignant mesotheliomas. BAP1 is a histone deubiquitinase involved in the DNA damage response, and germline BAP1 variants cause BAP1 tumor predisposition syndrome (BAP1 TPDS), increasing the risk of mesothelioma, uveal melanoma, cutaneous melanoma, renal cell carcinoma and others. BAP1 loss immunohistochemistry (IHC) is used as an adjunctive diagnostic tool for mesothelioma.
NF2 (neurofibromatosis type 2, merlin) is a tumor suppressor gene with biallelic inactivation in about 40–50% of mesotheliomas. Loss of merlin activates growth signaling pathways such as FAK, mTOR and RAC1. CDKN2A (p16) homozygous deletion is found in about 70–80% of malignant mesotheliomas and is a useful diagnostic marker for distinguishing it from benign reactive mesothelial proliferation. Inactivation of LATS1/LATS2 (Hippo pathway) is also reported in mesothelioma.
Because the TMB of mesothelioma is low (median TMB about 0.9–1.4 mut/Mb), TMB-based prediction of immunotherapy response is limited. However, PD-L1 expression is positive in about 20–40% of mesotheliomas, which is partly associated with responsiveness to immune checkpoint inhibitors. Epithelioid mesothelioma is reported to respond better to immunotherapy than the sarcomatoid and biphasic types.
Mesothelioma is a rare but lethal malignancy with about 30,000–40,000 cases worldwide each year. Incidence varies greatly by country according to the scale of asbestos exposure. Incidence is high in industrialized countries that used large amounts of asbestos (the UK, Australia, the US, Germany, Japan, etc.).
In Korea, a study based on 1994–2013 cancer registry data confirmed that mesothelioma incidence is continuously increasing, and incidence is projected to keep rising through 2038. This is the result of widespread asbestos use during Korea's rapid industrialization in the 1970s–1980s, as workers exposed at that time are now developing mesothelioma after a latency of 30–40 years. Korea banned asbestos entirely in 2009, but mesothelioma due to past exposure is expected to continue for decades.
Mesothelioma incidence is 3–5 times higher in men than in women, because men made up the majority of occupations with heavy asbestos exposure. The age of onset is highest mainly in elderly people in their 60s–70s. Histologically, it is classified as epithelioid (about 60%), biphasic (about 20%) and sarcomatoid (about 20%).
The development of malignant mesothelioma results from a complex biologic process caused by asbestos fibers.
Inhaled asbestos fibers penetrate deep into the lung and reach the pleura. Asbestos fibers are not broken down physically or chemically, so they remain permanently in the pleura and continuously provoke chronic inflammatory responses. Macrophages try to phagocytose the asbestos fibers but cannot remove them completely, resulting in frustrated phagocytosis, during which large amounts of reactive oxygen species (ROS) and reactive nitrogen species (RNS) are generated.
ROS cause oxidative damage to the DNA of pleural mesothelial cells, which accumulates errors during repeated DNA repair. As tumor suppressor genes such as NF2, BAP1 and CDKN2A undergo biallelic inactivation, cell cycle dysregulation, evasion of cell death and loss of contact inhibition occur. Cytokines secreted during inflammation (TNF-α, IL-1β, IL-6) persistently activate the NF-κB pathway, increasing expression of anti-apoptotic proteins. Release of HMGB1 (High Mobility Group Box 1) protein activates the NLRP3 inflammasome, promoting IL-1β production, which creates a tumor-promoting inflammatory environment that supports the growth of malignant mesothelial cells.
When pleural effusion is present, percussion on the affected side reveals dullness and breath sounds are decreased. When pleural thickening is severe, lung expansion is restricted by an 'armored pleura' (trapped lung, pleural peel). Reduced lateral chest volume and tracheal deviation due to pleural thickening may be observed. In patients with a history of asbestos exposure, pleural asbestos plaques may be found on chest X-ray or CT (these are benign lesions but evidence of asbestos exposure).
In peritoneal mesothelioma, abdominal distension due to ascites, shifting dullness, and a fluid wave are noted. An abdominal mass may be palpable, and signs of bowel obstruction may appear.
In end-stage pleural mesothelioma, involvement of the phrenic nerve can cause phrenic nerve palsy, resulting in elevation of the diaphragm. SVC syndrome may occur with mediastinal involvement. With chest wall infiltration, a chest wall mass or subcutaneous nodules are palpable.
There is currently no standard screening test for malignant mesothelioma in the general population. However, the following medical surveillance is recommended for high-risk groups with a history of asbestos exposure:
Chest CT (contrast-enhanced) is the key imaging test for diagnosing mesothelioma and evaluates the location, extent, and character (nodular, sheet-like) of pleural thickening. Mesothelioma is likely when pleural thickening involves the medial (mediastinal) pleura, interlobar pleura, or diaphragmatic pleura. Chest MRI is superior to CT for assessing involvement of the diaphragm, chest wall, and pericardium. PET-CT is used for staging mesothelioma, assessing resectability, and monitoring treatment response.
Thoracoscopic pleural biopsy (VATS) is the gold standard for tissue acquisition. A sufficient amount of tissue can be obtained to perform immunohistochemical and molecular testing. CT-guided percutaneous core needle biopsy is an alternative when VATS is not possible. Pleural fluid cytology alone has low diagnostic sensitivity (30~60%), so tissue biopsy is required.
| Marker | Mesothelioma | Lung adenocarcinoma (differential) |
|---|---|---|
| Calretinin | Positive (+) | Negative (-) |
| WT1 | Positive (+) | Negative (-) |
| CK5/6 | Positive (+) | Negative/weakly positive |
| D2-40 (podoplanin) | Positive (+) | Negative (-) |
| CEA, TTF-1, Napsin A | Negative (-) | Positive (+) |
| BAP1 IHC | Lost (suggests malignancy) | Retained |
| CDKN2A FISH | Homozygous deletion (confirms malignancy) | No deletion |
In the 2020 CheckMate 743 trial, the combination of nivolumab + ipilimumab significantly improved median overall survival compared with chemotherapy, 18.1 months vs. 14.1 months. The benefit was especially pronounced in non-epithelioid (sarcomatoid, biphasic) mesothelioma. Based on these results, the FDA approved nivolumab + ipilimumab in 2020 as first-line treatment for unresectable malignant pleural mesothelioma.
Pemetrexed + cisplatin (or carboplatin) has been the standard chemotherapy since 2003. In the 2016 MAPS trial, adding bevacizumab was shown to further prolong survival, so the three-drug combination is used in some patients. In the 2024 ASCO guideline update, the combination of pembrolizumab + pemetrexed + platinum agent was also added as a first-line treatment option.
Extrapleural pneumonectomy (EPP) and pleurectomy/decortication (P/D) are performed in selected patients. When complete resection is possible, trimodality therapy with postoperative chemoradiotherapy is performed at some centers, but it has not been established as standard.
In resectable peritoneal mesothelioma, cytoreductive surgery + hyperthermic intraperitoneal chemotherapy (HIPEC) has been reported to significantly improve the 5-year survival rate in selected patients.
Overall, malignant mesothelioma has a very poor prognosis.
| Treatment | Median survival | Notes |
|---|---|---|
| Nivolumab + ipilimumab (immunotherapy) | 18.1 months | CheckMate 743; 2-year survival rate 41% |
| Pemetrexed + cisplatin (chemotherapy) | 12.1~14.1 months | Conventional first-line chemotherapy |
| Three-drug combination (+ bevacizumab) | 18.8 months | MAPS trial |
| Peritoneal mesothelioma surgery + HIPEC | 35~50 months (selected patients) | Epithelioid, low tumor burden |
The overall 5-year survival rate of mesothelioma is only 5~10%. Epithelioid mesothelioma has a significantly better prognosis than the sarcomatoid type (median survival 18~24 months vs. 8~12 months), and performance status (PS), stage at diagnosis, age, and blood findings (platelet count, white blood cell count) are prognostic factors. With the introduction of immunotherapy, long-term survival of 2~3 years or more is becoming possible in some patients, but the prognosis remains poor in most patients.